Pathway tool
Webcast
Discussion and guidance on the characterization of EGFR mutation-positive tumor subtypes, appropriate sequencing of treatment and management of EGFR TKI resistance. Program launch date: 19th October 2020Webcast accreditation expiration date: 5th November 2021Treatment Pathway accreditation expiration date: 17th February 2022 https://vimeo.com/644307189 Introduction to the program Program director Faculty Learning objectives Accreditation Educational grant Introduction to […]
Targeting improved outcomes in EGFR-mutated NSCLC
Webcast Discussion and guidance on the characterization of EGFR mutation-positive tumor subtypes, appropriate sequencing of treatment and management of EGFR TKI resistance. Pathway Follow a patient’s progression using this interactive pathway as we support your clinical treatment decision-making supported by trial data and expert opinion. An expert-driven program addressing the optimal treatment strategy for patients […]
